Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Hikma Eyes Morocco With Acquisition

by Michael McCoy
October 10, 2011 | A version of this story appeared in Volume 89, Issue 41

Hikma Pharmaceuticals has acquired 63.9% of Société de Promotion Pharmaceutique du Maghreb (Promopharm) for $112.2 million and is launching a tender offer for the rest of the firm. London-based Hikma says Promopharm is the ninth-largest drugmaker in Morocco, with a 3.5% market share. Its annual sales of about $45 million offer significant growth potential, Hikma says, owing to its portfolio of high-quality branded generics and in-licensed products.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.